ArticleOncology letters2026
Association between antidepressant exposure and prognosis in breast cancer: A systematic review and meta-analysis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, the prognostic impact of antidepressant (AD) use on breast cancer (BC) outcomes remains unclear. The present study investigated the relationship between AD exposure and survival outcomes in patients with BC. PubMed, Web of Science, Embase and the Cochrane Library databases were systematically searched from inception to October 2025. The hazard ratio (HR) with its 95% confidence interval (CI) was used as the effect size. The primary outcomes of the present study were overall survival (OS) and BC-specific survival (BCSS). The protocol was registered with the International Prospective Register of Systematic Reviews database (study no. CRD420251232706). In total, nine studies comprising ~90,000 AD-exposed and >300,000 unexposed patients with BC were included. AD-exposed patients had worse OS (HR=1.28; 95% CI, 1.22-1.34; P<0.001) and BCSS (HR=1.16; 95% CI, 1.09-1.25; P<0.001) compared with the control group. In geographical subgroup analyses, AD-exposed patients in Europe demonstrated worse OS (HR=1.27; P<0.001) and BCSS (HR=1.18; P<0.001), and those in Asia had worse BCSS (HR=1.30; P<0.001); by contrast, for North America (P=0.671), no significant difference in BCSS was observed compared with non-exposed patients. By drug class, patients exposed to selective serotonin reuptake inhibitors (SSRIs) had worse OS (HR=1.34; P<0.001) and BCSS (HR=1.21, P<0.001) compared with non-exposed patients. Among individual SSRIs, no significant differences in BCSS were observed for sertraline (P=0.547), paroxetine (P=0.063) or fluoxetine (P=0.647), whereas citalopram exposure (HR=1.29; P<0.001) had worse BCSS compared with non-exposed patients. Tricyclic ADs demonstrated worse BCSS (HR=1.26; P<0.001) compared with the control group. Regarding exposure timing, both continuous (OS: HR=1.24; P<0.001; BCSS: HR=1.14; P<0.001) and post-diagnosis (OS: HR=1.32; P<0.001; BCSS: HR=1.22; P=0.001) exposure had worse prognosis compared with the control group. In conclusion, observational evidence suggested that AD exposure may be associated with worse BC prognosis, and this association appeared to be influenced by geographical regions and drug classes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.